IFN-beta

IFN-beta

IFN-beta Overview

Molecule Name
Interferon beta
Synonyms
IFNB1,Interferon beta,IFN-beta,IFB,IFNB
Drug Development Progress
Drugs in Clinical Trials6
Approved Drugs1
Highest Development StageApproved
Target Synonym
Interferon Beta 1,Interferon, Beta 1, Fibroblast,IFNB,IFB,IFF,Interferon-beta,IFN-beta,Fibroblast interferon,IFNB1,Interferon beta
Background
Human type I interferons (IFNs) are a large subgroup of interferon proteins that help regulate the activity of the immune system. Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The IFN-β proteins are produced in large quantities by fibroblasts. They have antiviral activity that is involved mainly in innate immune response. Two types of IFN-β have been described, IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate. Furthermore, IFN-β1 can bind to a IFNAR1-IFNAR2 heterodimeric receptor, and can also function with IFNAR1 alone and independently of Jak-STAT pathways.

IFN-beta Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
DazukibartPF-06823859Phase 3 ClinicalPfizer Inc
Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Muscular Diseases; Myositis; Polymyositis
Details
Peginterferon beta-1a (CinnaGen)Phase 3 ClinicalCinnagen
Multiple Sclerosis, Relapsing-Remitting
Details
VSV-IFNbeta-NISPhase 2 ClinicalVyriad
Angioimmunoblastic T-cell Lymphoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Histiocytoma; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
VSV-hIFNbeta-NIS (University of Tennessee)Phase 1 ClinicalThe University Of Tennessee
Endometrial Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Multiple Myeloma
Details
MEM-288MEM-288Phase 1 ClinicalMemgen
Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
SCD-153SCD-153Phase 1 ClinicalInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University, Sun Pharma Advanced Research Company Ltd
Alopecia Areata
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
PropagermaniumSK-818; SK-818CApprovedSanwa Kagaku Kenkyusho Co LtdSerocionJapanHepatitis BSanwa Kagaku Kenkyusho Co Ltd1994-01-01
Hepatitis B
Details